Date: 2014-12-15
Type of information: Nomination
Compound: chief medical officer
Company: Khondrion (The Netherlands)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 15, 2014, Khondrion announced the appointment of dr. Edwin Spaans, former director Clinical Development of Kinesis, as its new Chief Medical Officer. Dr. Spaans will be responsible for Khondrion’s clinical trial program of its frontrunner compound KH176. Dr.Spaans will start at Khondrion January 1st 2015.
Financial terms:
Latest news:
Is general: Yes
